Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%
Melbourne, Australia; 22 May 2024 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.
CYP-001 is Cynata’s Cymerus™ off-the-shelf iPSC[i]-derived MSC[ii] product for intravenous infusion, which is being investigated as a potential immune modulating treatment. [Read more…]